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Summary
Background Although CT scans are very useful clinically, potential cancer risks exist from associated ionising 
radiation, in particular for children who are more radiosensitive than adults. We aimed to assess the excess risk of 
leukaemia and brain tumours after CT scans in a cohort of children and young adults.
Methods In our retrospective cohort study, we included patients without previous cancer diagnoses who were ﬁ rst 
examined with CT in National Health Service (NHS) centres in England, Wales, or Scotland (Great Britain) between 
1985 and 2002, when they were younger than 22 years of age. We obtained data for cancer incidence, mortality, and 
loss to follow-up from the NHS Central Registry from Jan 1, 1985, to Dec 31, 2008. We estimated absorbed brain and 
red bone marrow doses per CT scan in mGy and assessed excess incidence of leukaemia and brain tumours cancer 
with Poisson relative risk models. To avoid inclusion of CT scans related to cancer diagnosis, follow-up for leukaemia 
began 2 years after the ﬁ rst CT and for brain tumours 5 years after the ﬁ rst CT.
Findings During follow-up, 74 of 178 604 patients were diagnosed with leukaemia and 135 of 176 587 patients were 
diagnosed with brain tumours. We noted a positive association between radiation dose from CT scans and leukaemia 
(excess relative risk [ERR] per mGy 0·036, 95% CI 0·005–0·120; p=0·0097) and brain tumours (0·023, 0·010–0·049; 
p<0·0001). Compared with patients who received a dose of less than 5 mGy, the relative risk of leukaemia for patients 
who received a cumulative dose of at least 30 mGy (mean dose 51·13 mGy) was 3·18 (95% CI 1·46–6·94) and the 
relative risk of brain cancer for patients who received a cumulative dose of 50–74 mGy (mean dose 60·42 mGy) was 
2·82 (1·33–6·03). 
Interpretation Use of CT scans in children to deliver cumulative doses of about 50 mGy might almost triple the risk of 
leukaemia and doses of about 60 mGy might triple the risk of brain cancer. Because these cancers are relatively rare, 
the cumulative absolute risks are small: in the 10 years after the ﬁ rst scan for patients younger than 10 years, one excess 
case of leukaemia and one excess case of brain tumour per 10 000 head CT scans is estimated to occur. Nevertheless, 
although clinical beneﬁ ts should outweigh the small absolute risks, radiation doses from CT scans ought to be kept as 
low as possible and alternative procedures, which do not involve ionising radiation, should be considered if appropriate.
Funding US National Cancer Institute and UK Department of Health.  
Introduction
CT imaging is a valuable diagnostic technique, and new 
clinical applications continue to be identiﬁ ed. As a result, 
the rates of CT use have increased rapidly in the USA and 
elsewhere, particularly in the past 10 years.1 Although the 
immediate beneﬁ t to the individual patient can be sub-
stantial, the relatively high radiation doses associated 
with CT compared with conventional radiog raphy have 
raised health concerns.2–8 Potential increases in future 
cancer risk, attributable to the rapid expansion in CT use 
have been estimated with risk projection models, which 
are derived mainly from studies of survivors of the atomic 
bombs in Japan.3,6,8 These studies have been criticised 
because of concerns about how applicable the ﬁ ndings 
from this group are to the relatively low doses of radiation 
exposure from CT scans and to non-Japanese populations. 
Some investigators claim that there are no risks, or even 
beneﬁ cial eﬀ ects, associated with low-dose radiation.9 No 
direct studies of cancer risk in patients who have 
undergone CT scans have been undertaken to date.
We did a study to directly assess the question of 
whether cancer risks are increased after CT scans in 
childhood and young adulthood. Here we assess the risks 
of leukaemia and brain tumours because they are the 
endpoints of greatest concern as the red bone marrow 
and brain are highly radiosensitive tissues, especially in 
childhood.10 Furthermore, these tissues are also some of 
the most highly exposed from childhood CT scans,11 and 
leukaemias and brain tumours are the most common 
childhood cancers.
Methods
Patients and study design
In our observational retrospective cohort study, we 
included patients without previous malignant disease 
who were ﬁ rst examined with CT between 1985 and 
Articles
500 www.thelancet.com   Vol 380   August 4, 2012
2002 when they were younger than 22 years of age. 
Patients were scanned at hospitals within 81 National 
Health Service (NHS) regional services in Great Britain 
(England, Wales, and Scotland). We assembled the cohort 
with historical data from electronic radiology information 
systems (RIS) from the participating hospitals or, for a 
small number of patients in ﬁ ve hospitals, from paper or 
ﬁ lm records. Retrieved data included date of birth, details 
of the CT examinations, sex, post code, and body parts 
scanned. We used the patient’s identiﬁ ers to identify 
patients having scans in more than one hospital.
This study was approved by the Newcastle and North 
Tyneside Local Research Ethics Committee (Newcastle 
upon Tyne, UK) and by the UK National Information 
Governance Board, exempting the study from requiring 
individual patient’s consent.
Procedures
Linkage with the NHS Central Registry (NHSCR) 
provided cancer incidence, mortality and loss-to-follow-up 
data (eg, notiﬁ ed emigrations) from Jan 1, 1985, to 
Dec 31, 2008. The NHSCR holds compu terised records 
of everyone registered with an NHS general practitioner 
in Great Britain (most residents). It is continuously 
updated with births, deaths, marriages, name changes, 
and movements of patients, and records cancer 
incidence from the regional cancer registries. We 
excluded patients from the cohort who had an exit date 
of less than 2 years in the case of leukaemia or less than 
5 years for brain tumours after the ﬁ rst scan to reduce 
the possibility of inclusion of patients who had CT scans 
because a cancer was suspected. We also excluded 
patients who could not be traced by NHSCR, and those 
who had missing information or inaccurate information 
on the date of CT scan.
The appendix shows details of the morphology 
codes used to deﬁ ne leukaemias. We examined four non-
mutually exclusive leukaemia subgroups, which were 
acute lymphoblastic leukaemia, acute myeloid leukaemia, 
myelodysplastic syndromes, and leukaemia excluding 
myelodysplastic syndrome. We deﬁ ned malig nant and 
benign brain tumours with WHO’s Inter national 
Classiﬁ cation of Diseases for Oncology, 3rd edition 
topographic codes for meninges, brain, olfactory, and 
cranial nerves, and other parts of the CNS (spinal 
tumours were excluded). We examined two subgroups: 
glioma and meningioma plus schwan noma (appendix).
CT scans deliver very non-uniform radiation doses 
across the body. Therefore, we assessed the risk of 
leukaemia and brain tumours in relation to estimated 
radiation absorbed doses in the appropriate organ (red 
bone marrow or brain), which were estimated for each 
type of scan without knowledge of case status. The 
absorbed dose from a CT scan depends on factors 
including age, sex, examination type, and year of scan. 
Data for the machine settings that also inﬂ uence dose, 
such as milliampere seconds and peak kilovoltage, were 
not available for every individual patient from the 
electronic databases during the study period. Therefore, 
we obtained typical machine settings for CT in young 
people from UK-wide surveys undertaken in 1989 and 
2003.11,12 We combined these data with those from a series 
of hybrid computational human phantoms13 and Monte 
Carlo radiation transport techniques to estimate absorbed 
doses to the red bone marrow and brain for reference 
males and females for integer years of age between 0 and 
22 years.14,15 Table 1 shows estimated red bone marrow 
and brain doses from diﬀ erent CT examinations by age 
and sex after 2001. Dose estimates before 2001 were 
generally 2–3 times higher than were those after this date 
because age-speciﬁ c technical settings were rarely used 
in earlier years.12
Statistical analysis
We assessed potential associations between radiation 
dose and cancer outcomes with Poisson relative risk 
models ﬁ tted by maximum likelihood (see appendix). To 
avoid inclusion of CT scans related to cancer diagnosis 
we began accrual of person-time for leukaemia inci-
dence 2 years after the ﬁ rst CT scan and for brain 
tumours 5 years after the ﬁ rst CT scan. We continued 
accrual of data until date of ﬁ rst cancer diagnosis or the 
Male patients Female patients
Brain dose (mGy) Red bone marrow 
dose (mGy)
Brain dose (mGy) Red bone marrow 
dose (mGy)
Age at brain CT
0 years 28 8 28 8
5 years 28 9 28 9
10 years 35 6 35 6
15 years 43 4 44 6
20 years 35 2 42 2
Age at chest CT
0 years 0·4 4 0·4 4
5 years 0·3 3 0·3 3
10 years 0·3 3 0·3 3
15 years 0·2 4 0·3 4
20 years 0·2 4 0·3 4
Age at abdominal CT
0 years 0·2 3 0·2 3
5 years 0·1 2 0·1 2
10 years 0·1 3 0·1 3
15 years 0·0 3 0·0 3
20 years 0·0 3 0·0 4
Age at extremity CT
0 years 0·0 1 0·0 1
5 years 0·0 0·2 0·0 0·2
10 years 0·0 0·1 0·0 0·1
15 years 0·0 0·0 0·0 0·0
20 years 0·0 0·0 0·0 0·0
Table 1: Estimated radiation doses to the brain and red bone marrow from one CT scan, by scan type, sex, 
and age at scan, as used in this study for scans after 2001
See Online for appendix
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earliest of death, loss-to-follow-up, or Dec 31, 2008. 
Because it typically takes at least 2 years for radiation-
related leukaemia to develop and 5 years for a solid 
cancer to develop,16 doses were lagged by 2 years for 
leukaemia and by 5 years for brain tumours. Application 
of the exclusions and lag periods are described in the 
appendix. We did sensitivity analyses in which the 
exclusion and lag periods were increased to 10 years for 
brain tumours, the follow-up period for leukaemia was 
decreased from 2008 to 2004, and the age at end of 
follow-up was restricted to patients younger than 
25 years for leukaemia and younger than 28 years for 
brain tumours. We did signiﬁ cance tests on the basis of 
the likelihood-ratio test. Unless otherwise stated, we 
based CIs on the proﬁ le likelihood.17 When the statistical 
software failed to produce a convergent proﬁ le likelihood 
bound we used the Wald-based (Fisher information-
based) conﬁ dence bound. All p values are two-sided and 
p<0·05 was regarded as signiﬁ cant. We did all statistical 
analyses with the DATAB and AMFIT modules of the 
EPICURE programme.18
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. MSP and ABdG had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
After exclusion of 33 372 patients who could not be traced 
by NHSCR because of incomplete names or dates of 
birth in the RIS databases (and 960 non-UK resident 
Leukaemia* Brain tumours†
Cases Person-years Cases Person-years
Sex
Male 42 953 634 65 657 169
Female 31 764 937 70 529 372
Unknown 1 2413 0 1666
Age at ﬁ rst exposure, years
0 10 198 052 17 139 414
1–<5 17 262 437 18 185 942
5–<10 17 269 369 27 189 415
10–<15 10 345 320 30 236 891
≥15 20 645 807 43 436 545
Attained age, years
0–<20 47 900 383 65 537 567
20–<30 23 689 274 53 519 313
30–<35 2 106 376 12 106 376
≥35 2 24 951 5 24 951
Years since ﬁ rst exposure
0–<10 53 1 266 110 77 733 337
10–<15 15 347 786 45 347 786
15–<20 6 101 213 13 101 213
≥20 0 5871 0 5871
Number of CT scans
1 45 1 239 170 72 862 661
2–4 22 429 324 50 291 192
≥5 7 52 493 13 34 354
Overall 74 1 720 984 135 1 188 207
Person-year data in the leukaemia group do not sum to the overall number 
because of rounding. *Follow-up starting 2 years after ﬁ rst CT scan. †Follow-up 
starting 5 years after ﬁ rst CT scan.
Table 2: Cases of leukaemia and brain tumours and person-years for 
patients in the assessed cohort
Figure: Relative risk of leukaemia and brain tumours in relation to estimated 
radiation doses to the red bone marrow and brain from CT scans
(A) Leukaemia and (B) brain tumours. Dotted line is the ﬁ tted linear 
dose-response model (excess relative risk per mGy). Bars show 95% CIs.
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patients) and those who were ineligible for follow-up 
because the exit date occurred less than 2 years in the 
case of leukaemia analyses or 5 years for brain tumours 
after the ﬁ rst scan (or when information, such as date of 
scan, was missing or obviously inaccurate), we included 
178 604 individuals in the leukaemia analyses and 
176 587 in the brain tumour analyses (table 2).
We included 283 919 CT scans in the analysis of 
leukaemia risk, of which 64% (182 337 scans) were of the 
head. The next most common CT scan types were of the 
abdomen and/or pelvis (9%, 25 695 scans) and chest CT 
(7%, 18 910 scans; appendix). The distribution of scan 
types was very similar for patients in the brain tumour 
analysis, but the total number of scans was slightly 
smaller than in the leukaemia analysis because of the 
longer exclusion period (279 824 scans). Table 2 lists the 
distri butions of cases and overall person-years, by sex, 
age at ﬁ rst scan, attained age, years since ﬁ rst scan, and 
the number of scans.
The risk of leukaemia was positively associated with 
estimated doses delivered by CT scans to the red bone 
marrow (p=0·0097), as was the risk of brain tumours 
associated with estimated doses delivered by CT scans to 
the brain tissue (p<0·0001; ﬁ gure).
Compared with doses of less than 5 mGy, the relative 
risk (RR) of leukaemia for patients who received doses 
of at least 30 mGy (mean dose in this group was 
51·13 mGy) was 3·18 (95% CI 1·46–6·94; appendix). 
Compared with doses of less than 5 mGy, the RR of 
brain tumours for patients receiving 50–74 mGy 
(mean dose 60·42 mGy) was 2·82 (1·33–6·03; ﬁ gure, 
appendix), and for patients receiving 50 mGy or more 
(mean dose 104·16 mGy) the brain tumour RR is 3·32 
(95% CI 1·84–6·42; appendix). To put this into context, 
after 2001, 5–10 head CTs in children younger than 
15 years result in the accumulation of about 50 mGy red 
bone marrow dose and 2–3 head CTs results in about a 
60 mGy cumulative brain dose (table 1).
We noted positive associations between CT scans and 
cancer subgroups of gliomas (p=0·0033), schwannoma 
and meningiomas (p=0·0195), acute lymphoblastic 
leukaemia (p=0·0053), and myelodysplastic syndromes 
(p=0·0032), but not acute myeloid leukaemia (p=0·2653) 
or leukaemia excluding myelodysplastic syndromes 
(p=0·1436; table 3). For leu kaemia, the dose response did 
not vary between age at exposure, time since exposure, 
sex, or any other co variates examined (table 4). However, 
for brain tumours there was signiﬁ cant heterogeneity 
(p=0·0003) in estimated RR (ERR) across categories of 
age at exposure, with ERR increasing with increasing age.
We noted little evidence of non-linearity of the 
dose-response, using either linear-quadratic or linear-
exponential forms of departure from linearity (leukaemia 
exponential p=0·2672 and quadratic p=0·4683, brain 
tumour exponential p=0·9203 and quadratic p=0·8993). 
In sensitivity analyses in which all scans 10 years before 
brain tumour diagnosis were excluded, the magnitude of 
the dose-responses was increased rather than decreased 
as might be expected if the association was driven by bias 
from CT scans related to the diagnosis (appendix). When 
Cases ERR per mGy (95% CI) p value (test for 
dose-response)
Red bone marrow dose
All leukaemia, including myelodysplastic syndromes 74 0·036 (0·005 to 0·120) 0·0097
Acute lymphoblastic leukaemia 26 1·719* (>0 to 17·73†) 0·0053
Acute myeloid leukaemia 18 0·021 (–0·042† to 0·155) 0·2653
Myelodysplastic syndromes 9 6·098* (>0 to 145·4†) 0·0032
Leukaemia excluding myelodysplastic syndromes 65 0·019 (–0·012† to 0·079) 0·1436
Brain dose
All brain 135 0·023 (0·010 to 0·049) <0·0001
Glioma 65 0·019 (0·003 to 0·070) 0·0033
Schwannoma and meningioma 20 0·033 (0·002 to 0·439) 0·0195
ERR=excess relative risk. *Iteratively reweighted least-squares algorithm failed to converge, so parameter estimates 
might be unreliable. †Calculated using Wald-based CI.
Table 3: Excess relative risk per mGy for cancer subtypes in relation to organ-speciﬁ c radiation doses 
received from CT scans
Leukaemia Brain tumours
ERR per mGy p value ERR per mGy p value
Sex
Male* 0·031 0·6300 0·016 0·0850
Female 0·042 0·028
Years since ﬁ rst exposure
0–<5 0·048 0·8061 0† 0·6468
5–<10 0·033 0·025
≥10 0·026 0·021
Years since last exposure
0–<5 0·052 0·3004 0† 0·1976
5–<10 0·015 0·026
≥10 0·014 0·016
Number of CT scans
1 0·013 0·8013 0·007 0·1213
2–4 0·028 0·021
≥5 0·035 0·018
Age at exposure (years)‡
0–<5 0·030 0·5381 0·005 0·0003
5–<10 0·072 0·028
10–<15 –0·002 0·037
≥15 0·049 0·041
Years since exposure‡
2–<5 0·055 0·5357 ·· 0·2399
5–<10 0·021 0·026
10–<15 0·005 0·023
≥15 0·026 0·005
ERR=excess relative risk. ··=not applicable (follow-up started at 5 years). 
*Includes individual of unknown sex. †Aliased parameter, set to zero. 
‡Time-dependent variable.
Table 4: Excess relative risk per mGy for leukaemia and brain tumours, 
by various personal characteristics
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follow-up for leu kaemia was restricted to 2004, the dose-
response also increased, which was as expected given the 
short latency period for leukaemia and early peak in excess 
risk reported in previous studies.10,16 To assess whether the 
missing exposure data after age 22 years resulted in 
underestimation of doses and hence over estimation of the 
relative risks, we restricted follow-up to individuals 
younger than 28 years for brain tumours and individuals 
younger than 25 years for leukaemia, but this did not 
change the dose-response estimates.
Discussion
In this retrospective cohort study, we show signiﬁ cant 
associations between the estimated radiation doses 
provided by CT scans to red bone marrow and brain and 
subsequent incidence of leukaemia and brain tumours. 
Assuming typical doses for scans done after 2001 in 
children aged younger than 15 years, cumulative ionising 
radiation doses from 2–3 head CTs (ie, ~60 mGy) could 
almost triple the risk of brain tumours and 5–10 head 
CTs (~50 mGy) could triple the risk of leukaemia.
Although no previous cohort studies have assessed the 
risk of cancer after CT, several studies have reported 
signiﬁ cantly increased cancer risks after radiation 
exposure in the range received from multiple CT scans 
(100 mGy).19 Such studies include those of survivors of 
the atomic bombs in Japan,20 nuclear workers,21 and 
patients who received tens of diagnostic radiographs.22 A 
few case-control studies have also assessed cancer risks 
from CT scans on the basis of self-reported history of 
diagnostic radiograph exposures.23,24 These studies might 
be subject to recall bias whereby patients are more likely 
to recall previous medical radiation exposures than are 
unaﬀ ected controls, and also high levels of reporting 
error. We avoided such bias by taking a cohort approach 
and assessing more accurate exposure histories from 
medical records (panel).
In terms of the quantitative estimates of the risk, our 
primary comparison for leukaemias and brain tumours 
is with the Life Span Study20 of Japanese atomic bomb 
survivors, which is the most comprehensive study of 
cancer after radiation exposure currently available.10,16 
The dose-response for leukaemia following childhood 
exposure and similar follow-up time (<15 years after 
exposure) in the Life Span Study was 0·045 per mSv 
(95% CI 0·016–0·188; appendix) which was much the 
same as our estimate (ERR of 0·036 per mGy 
[0·005–0·120]; 1 mSv=1 mGy). For brain tumours, our 
result (ERR 0·023 per mGy [0·010–0·049]) was about 
four times higher than was the Life Span Study estimate 
(0·0061 per mSv [0·0001–0·0639] <20 years after 
exposure; appendix), but the CIs are wide and over-
lapped. We had reduced power to examine risks by 
subtype of neoplasm, age, or time since exposure 
compared with the Life Span Study, partly because of the 
more restricted ranges of length of follow-up and age at 
exposure. The increased risks noted in our study 
compared with the Life Span Study might be because 
existing tumours in some patients were not detected at 
the time of their ﬁ rst CT. The relatively low-energy 
x-radiation from CT scans might also be about twice as 
biologically eﬀ ective per unit dose as the mainly high-
energy γ-rays that were the predominant exposure source 
from the atomic bombings in Hiroshima and Nagasaki.16
Our large study sample was collected from a wide 
range of hospitals in Great Britain. Because most 
medical attendances at hospitals in Great Britain, 
particularly for the age group in this study, are in public, 
free-to-access, NHS hospitals, the sample is probably 
representative of the childhood and young adult 
population in the country as a whole who undergo CT. 
Ascertainment of cancer diagnoses by NHSCR is 
estimated to be 97%25 and therefore there is a low 
likelihood of losses to follow-up. Patients who were 
excluded because linkage to their records was not 
possible had similar characteristics to those who were 
linked and thus should not have biased conclusions. 
Because we assessed children and young adults, our 
results are directly applicable to a highly radiosensitive 
section of the population,10 although whether the results 
can be generalised to adulthood CT scans has not been 
established. Moreover, because most (>80%) of the 
population assessed was white, whether the results are 
generalisable to other ethnic groups is unknown.
CT is often used as a diagnostic technique when a solid 
cancer is suspected. However, information about the 
reasons for CTs and other clinical variables were not 
available for this study. Instead, we excluded all scans 
undertaken in the 2 years before a leukaemia diagnosis 
and 5 years before a brain tumour diagnosis. Young 
Panel: Research in context
Systematic review
We searched PubMed and Medline databases without date or language restriction for 
articles with the search terms “computed tomography”, “ionizing radiation”, “cancer”, 
“radiation-induced neoplasms”, “case-control”, and “prospective”. We reviewed reports 
from scientiﬁ c committees such as the International Commission on Radiological 
Protection (ICRP), United Nations Scientiﬁ c Committee on the Eﬀ ects of Atomic Radiation 
(UNSCEAR), and Biological Eﬀ ects of Ionizing Radiations (BEIR), and also a broader range 
of publications and reports covering medical imaging and radiation exposure. We checked 
references from selected publications for relevance to this study including comments, 
correspondence, and editorials. Exposure to ionising radiation is an established risk factor 
for leukaemia and brain tumours.10,16 Although CT has important clinical uses, concerns 
exist about the potential cancer risks from the associated ionising radiation, particularly 
for children. Rates of CT use have been rising rapidly in the developed world.
Interpretation
Increases that we noted in incidence rates of leukaemia and brain tumours after 
childhood exposure to CT scans are unlikely to be due to confounding factors. The 
evaluated risks per unit dose were consistent with those derived from recent analyses of 
cohorts exposed to higher average radiation doses and dose rates. The current study 
supports the extrapolation of such risk models to doses from CT scans.
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patients with leukaemia are unlikely to have a CT because 
of their disease,26 but we still used a cautious approach of 
applying an exclusion period. By contrast, patients with 
brain tumours will probably have a number of CT 
examinations during the diagnostic period, hence the 
longer exclusion period. Nevertheless, we noted much 
the same results in sensitivity analyses in which all scans 
in the 10 years before a brain tumour diagnosis were 
excluded. The absence of data for other exposures, such 
as radiographs, is unlikely to have introduced a major 
bias because the doses from these scans are typically ten-
times smaller than those for CT scans. However, we 
cannot rule out this bias and the increased dose response 
noted for brain tumours compared with the survivors of 
the atomic bombs in Japan is also a possible indication of 
some residual bias despite the long exclusion period.
Previous dose estimates for CT typically provided 
eﬀ ective dose rather than organ doses and were restricted 
in terms of the ages covered. In this study, a series of 
phantoms with a higher age resolution from newborn to 
adult was used for both males and females. We also used 
more realistic anatomy and bone marrow dosimetry 
models compared with previous computational phan toms. 
These advanced features allow more accurate and valid 
estimates of organ-speciﬁ c doses. Despite these advanced 
methods, uncertainties exist for our dose estimates. 
However, such uncertainties are likely to be mainly 
Berksonian (resulting from applying group-averaged 
estimates), and thus would not be expected to bias the dose 
response.27 Collection of detailed scan parameter data for 
individual patients was not possible. Instead, we used 
average CT machine settings from two national surveys 
and assumed that no technical adjust ment was made for 
paediatric patients before 2001.5
 Absolute excess risk estimates are necessary to put the 
risks into perspective with the beneﬁ ts of the scans. Good 
evidence from the long-term study of the atomic bomb 
survivors in Japan suggests that cancer risk persists 
indeﬁ nitely after radiation exposure and most cancer 
types are inducible by radiation.10,16 At present, we only 
have suﬃ  cient case numbers to assess brain tumours 
and leukaemia, and the maximum age of patients at the 
end of follow-up is 45 years, with a minimum age of 
6 years and maximum follow-up time of 23 years. 
Provisional estimates of excess absolute risk for the end 
of follow-up at about 10 years after exposure suggest that, 
of 10 000 people between the ages of 0–20 years receiving 
10 mGy from a CT scan, there would be about 0·83 
(95% CI 0·12–2·77) excess leukaemia cases and 0·32 
(0·14–0·69) excess brain tumours (appendix). Applying 
the dose estimates for one head CT scan before the age of 
10 years (table 1) this estimate would translate into 
approximately one excess case of leukaemia and one 
excess brain tumour per 10 000 patients. Increased 
follow-up and analysis of other cancer types is needed to 
identify the lifetime excess cancer risk associated with 
CT scans. Some evidence28 suggests that doses in the 
range delivered by several CT scans might increase the 
risk of cardiovascular disease. Investigating this feature 
would require not only the same long-term follow-up 
required for adulthood cancer outcomes, but also a new 
approach to obtain cardiovascular incidence data, which 
is not currently recorded on a registry rather than reliance 
on mortality data.
Various studies have estimated the potential lifetime 
excess cancer risks from CT scans from risk projection 
models, which are largely based on risk models from 
studies of survivors of the atomic bombs in Japan. 
Because our relative risk estimates are broadly consistent 
with the results from the Life Span Study, this study 
provides additional direct support for the existing life-
time absolute cancer risk projections for paediatric 
patients.3,7,8,29 The most recent risk projections8 suggest 
that, for children with normal life expectancy, the lifetime 
excess risk of any incident cancer for a head CT scan 
(with typical dose levels used in the USA) is about one 
cancer per 1000 head CT scans for young children 
(<5 years), decreasing to about one cancer per 2000 scans 
for exposure at age 15 years. For an abdominal or pelvic 
CT scan, the lifetime risks for children are one cancer 
per 500 scans irrespective of age at exposure. These 
absolute excess lifetime cancer risks (to age 100 years) are 
very small compared with the lifetime risk of developing 
cancer in the general population, which is about one in 
three, and are also likely to be small compared with the 
beneﬁ ts of the scan, providing it is clinically justiﬁ ed.1
We estimated doses for each scan that every patient 
received, obtained outcome data for the patients, and 
provided direct evidence that doses at the level children 
and young adults can receive from CT are associated 
with increased risks of leukaemia and brain tumours. 
The dose-response relation that we noted and relative 
risks of more than 2 for an exposure that is an established 
carcinogen at higher dose-levels10,16 is evidence that this 
relation is unlikely to be entirely due to confounding 
factors. With the increasing use of CT worldwide, 
particularly within this young population,8 knowledge of 
the risks based on empirical data will be crucial to assess 
safety in relation to the beneﬁ ts that CT provides. 
Frequent calls have been made to decrease doses, 
following the as low as reasonably achievable (ALARA) 
principle, and only scan when justiﬁ ed as in the current 
image gently campaign.30 In the UK, the Ionising 
Radiation (Medical Exposure) Regulations mean that a 
CT scan should only be done when clinically justiﬁ ed, 
which might explain the low levels of CT use in the UK 
compared with other countries that do not have such 
regulations. The immediate beneﬁ ts of CT outweigh the 
long-term risks in many settings31 and because of CT’s 
diagnostic accuracy and speed of scanning, notably 
removing the need for anaesthesia and sedation in 
young patients, it will remain in widespread practice for 
the foreseeable future. Further reﬁ nements to allow 
reduction in CT doses should be a priority, not only for 
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the radiology community but also for manufacturers. 
Alternative diagnostic procedures that do not involve 
ionising radiation exposure, such as ultrasound and 
MRI might be appropriate in some clinical settings.
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